Indeed, the anti-tumor efficacy of SC144@HABN + anti-PD-L1 combo therapy was abrogated by co-treatment with anti-IL-6 antibody, (Supplementary Fig. 21), highlighting an important role of IL-6 modulated by SC144@HABN + anti-PD-L1 combo therapy. Here, IL6 is linked to neoplasm.